Paras Healthcare: Board Approves Q2 FY27 Unaudited Financial Results
RESULTS
● No Immediate Change
LOW RISK
📅 Filed on BSE: 05 Nov 2026, 07:26 PM IST · BSE ID: e08773b0-3e8c-48ea-b023-8f6114cfa1c7
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board approved its financial results for the latest quarter and half-year, and decided to continue a director's term.
🤖 AI Summary
- Board approved unaudited standalone and consolidated financial results for Q2 FY27 and half year ended September 30, 2026.
- Continuation of Mr. Kabir Kishin Thakur as Non-Executive Non-Independent Director approved, subject to shareholder approval.
- Mr. Thakur brings over 19 years of experience in investment and private equity to the board.
- M/s. Walker Chandiok & Co LLP issued unmodified Limited Review Reports on the financial results.
🏢 How This Affects the Company
The continuation of Mr. Kabir Kishin Thakur's directorship is subject to shareholder approval, introducing a dependency on shareholder voting.
👥 What This Means For Shareholders
✅
Action Required
Shareholders will need to vote on the continuation of Mr. Kabir Kishin Thakur as a Non-Executive Non-Independent Director at an upcoming meeting.
👤
Who Is Affected
All shareholders will be affected by the decision regarding Mr. Kabir Kishin Thakur's directorship as it requires their approval, influencing board composition.
🔍
Management Signal
Management intends to retain Mr. Kabir Kishin Thakur, a director with 19 years of investment and private equity experience, indicating a preference for continuity in strategic oversight.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List - track these upcoming events
Review the full Q2 FY27 financial results once made publicly available.
Monitor shareholder meeting dates for the resolution on Mr. Kabir Kishin Thakur's directorship.
Assess any future board decisions or appointments for potential changes in governance.
LOW RISK
Filing indicates routine approvals, with no immediate adverse financial or operational risks disclosed.
💡 Investor Takeaway
The Board of Paras Healthcare Ltd. has approved its unaudited standalone and consolidated financial results for Q2 FY27 and the half year ended September 30, 2026. Additionally, the continuation of Mr. Kabir Kishin Thakur as a Non-Executive Non-Independent Director was approved, pending shareholder resolution.
📅 Company Track Record
No previous filings found for Paras Healthcare Ltd (BSE: 545005) to establish historical financial performance or corporate actions. Limited public track record is available.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What financial period do the approved results for Paras Healthcare Ltd cover?
The approved unaudited standalone and consolidated financial results for Paras Healthcare Ltd cover the quarter and half year ended September 30, 2026, which corresponds to Q2 FY27.
What decision did the Board make regarding Mr. Kabir Kishin Thakur?
The Board approved the continuation of Mr. Kabir Kishin Thakur (DIN: 08422362) as a Non-Executive Non-Independent Director, subject to the approval of the Company's Shareholders.
What is the professional background of Mr. Kabir Kishin Thakur?
Mr. Kabir Kishin Thakur has over 19 years of experience in investment and private equity, having previously been associated with ChrysCapital Group and Citibank’s investment banking division.
Which auditors reviewed Paras Healthcare's Q2 FY27 financial results?
M/s. Walker Chandiok & Co LLP, Chartered Accountants (Firm Registration No. 001076N/N500013), the Statutory Auditors, issued unmodified Limited Review Reports on the financial results.
Questions based on this BSE filing only. For information purposes.